News & Press Releases

Mintz advised the underwriters in connection with Benitec Biopharma’s follow-on public offering of 5,930,000 shares of common stock at a public offering price of $13.50 per share, and the placement agents in the concurrent registered direct offering of 1,481,481 shares of common stock at an offering price of $13.50 per share. The aggregate gross proceeds to Benitec Biopharma from these offerings were approximately $100 million before deducting underwriting discounts and commissions, placement agent fees, and other offering expenses. In addition, Benitec Biopharma granted the underwriters a 30-day option to purchase up to an additional 889,500 shares of its common stock at the public offering price.

Mintz advised the underwriter in connection with a $75 million underwritten offering by MoonLake Immunotherapeutics of 7,142,857 Class A ordinary shares at an offering price of $10.50 per share. The aggregate gross proceeds to MoonLake Immunotherapeutics from this offering were approximately $75 million before deducting underwriting discounts and commissions and other offering expenses.

Benchmark Litigation has recognized 19 Mintz attorneys in its 2026 guide and named Mintz a Highly Recommended Firm in Massachusetts. The firm also achieved national Tier 2 rankings in the Commercial Litigation, Insurance, and White Collar categories.

Mintz advised the underwriters in connection with a $603 million public offering by Praxis Precision Medicines of 3,527,072 shares of common stock (which includes 501,592 shares of common stock issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock) at a public offering price of $157.00 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 318,470 shares of common stock at the public offering price per share less the $0.0001 per share exercise price of each pre-funded warrant. The aggregate gross proceeds to Praxis Precision Medicines from this offering were approximately $603 million before deducting underwriting discounts and commissions and other offering expenses.

Mintz advised the placement agents in connection with Spruce Biosciences, Inc.'s $50 million private placement.  The investors purchased common stock (and pre-funded warrants in lieu of common stock for certain investors).

Mintz represented VMG Partners, a growth equity firm with a two-decade track record of scaling iconic consumer brands, in its partnership with Scenthound, the nation's first and leading dog wellness franchise. VMG’s investment will reinforce Scenthound’s leadership in the pet industry and accelerate its mission of revolutionizing pet care through routine hygiene and wellness.